Should We Raise Our Prices?
in Healthcare Providers

The short answer

The question is never whether to adjust terms on value-based contracts in general. It is which attributed lives, by how much per episode, and what loss in panel size or contracts you expect. For healthcare providers, this shows up in a particular place. The numbers that carry the answer are cost per episode and payer mix, and the complication specific to this industry is that downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. The general version of this problem and the one you are actually in have different first moves.

Contract terms on attributed lives is the fastest lever in this setting — it requires no new lives, no added providers and no new service lines, and it arrives on the next settlement cycle. It is also the one operators are most reluctant to touch, which is why contracts that leave downside risk on 38,000 lives without cost-per-episode data remain in place.

A useful analysis does not produce one number. It produces a segmentation by payer mix and panel: which attributed lives show cost per episode below the contracted value, which have already reached the ceiling of what the contract will bear, and where variation in contribution per provider shows terms being set by individual negotiations rather than by policy.

The uncomfortable part is that a good adjustment deliberately loses some attributed lives or contracts. If the change costs you none, the terms were still too low relative to cost per episode.

How to tell this is actually your problem

These three together are the signature. One on its own usually points somewhere else.

✓ Almost every value-based contract is accepted on first submission
✓ Contribution per provider shows wide unexplained differences across the same payer mix
✓ Cost per episode has increased while the terms attached to the 38,000 attributed lives have stayed unchanged

The move that usually makes it worse. A uniform shift in terms across all 38,000 attributed lives, which overprices some segments of the payer mix and still underprices the episodes that drive the highest cost per episode.

Who this is for — and who it is not

It is for you if you run or finance a healthcare provider and almost every deal closes, and closes quickly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

What this looks like when the analysis is actually run

Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.

The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.

This is one move out of a full analysis. Read a complete report — every page, no email required.

What the engine does with this question

This question routes to Pricing & Revenue Optimization, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.

Questions people ask about this

How much can I raise prices without losing customers?

There is no general answer, and the useful analysis is per segment. What can be said is that the loss you fear is usually concentrated in a group whose economics you would improve by losing them.

Should I raise prices for existing customers or only new ones?

New first is safer and slower; existing is where the money is. A defensible sequence is to move new-customer pricing, watch win rate for a quarter, then bring existing customers up at renewal with notice.

What if my competitors are cheaper?

Then you are selling against them on something other than price, or you are not — and that is the real question. Competing on price without the cost structure to support it is the most reliable way to lose money at increasing volume.

Is this different in healthcare providers than in other industries?

Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a healthcare provider?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.